Clinical pharmacology programs designed and implemented by us often incorporate additional endpoints, including the effect of food, the effect of age or gender, and pharmacodynamic or biomarker assessments. It is also common to complement a first-in-human to proof-of-concept program with a small patient cohort under a single protocol and regulatory submission.